The study team described a mineralized, three-dimensional scaffold integrated with a forced perfusion bioreactor to generate mature, dendrite-bearing osteocytes in vitro. The authors reported they optimized perfusion parameters to support interconnected dendritic networks that resembled mature osteocyte morphology. The differentiated MPC-2 cells used in the platform displayed classical functional behaviors, including responsiveness to parathyroid hormone and robust flow-induced suppression of Sost, establishing the system as a physiologically relevant model for mechanotransduction studies.
Investigators exposed the 3D mature osteocytes to conditioned media (CM) from two breast cancer cell lines representing different molecular subtypes: estrogen receptor–positive (ER+; ZR-75-1) and triple-negative (TN; MDA-MB-231). Tumor CM was collected 24 hours after irradiation of the tumor cells at either 0 or 2 Gy; the authors evaluated downstream osteocyte transcriptional endpoints Tnfsf11, Tnfrsf11b and Sost as functional readouts of mechanosensing. Data indicated a clear subtype dependence: CM from non-irradiated ER+ cells allowed the canonical, flow-induced downregulation of Sost to occur in osteocytes, preserving mechanoresponsiveness. By contrast, TN CM blunted flow-induced Sost suppression regardless of whether the TN cells had been irradiated.
The cohort observations suggested that the molecular identity of the breast tumor—rather than irradiation status alone—was the primary determinant of secretome effects on osteocyte mechanotransduction. The study team observed that TN-derived secretomes impaired this specific anabolic osteocyte response even in the absence of radiation exposure, implying subtype-specific tumor–bone signaling that can negate mechanical cues.
When ER+ tumor cells received 2 Gy radiation prior to CM collection, osteocyte mechanoresponsiveness changed markedly. The authors reported that ER+ CM collected after 2 Gy irradiation eliminated the flow-induced suppression of Sost that was present with non-irradiated ER+ CM. Radiation thus introduced a directional change in the ER+ secretome sufficient to disrupt a canonical mechanotransduction endpoint in mature osteocytes.
The study did not claim broader clinical radiation dose–response relationships beyond the 0 versus 2 Gy conditions used. The authors limited their statements to the experimental parameters reported and to the transcriptional endpoints measured in the osteocytes.
To characterize tumor-derived factors that might mediate these effects, the investigators profiled conditioned media using an 84-target oncology proteomic panel. Authors noted that breast cancer subtype emerged as the dominant driver of secretome composition across the panel. They also observed that a 2 Gy radiation exposure generated distinct, directional shifts in secretome composition that differed between ER+ and TN cells.
The source did not list individual protein changes or absolute concentrations in the abstract; the authors instead concluded that subtype identity strongly shaped the secretome and that low-dose radiation produced measurable alterations that were not uniform across subtypes. These proteomic data framed potential tumor-derived targets for strategies aiming to restore osteocyte mechanosensing in metastatic bone disease.
The team validated the 3D perfused system with functional and transcriptional endpoints relevant to bone remodeling. Flow-induced suppression of Sost served as a primary mechanotransduction readout; the study also reported parathyroid hormone responsiveness, which supports endocrine sensitivity of the differentiated osteocyte population. Transcriptional measurement of Tnfsf11 and Tnfrsf11b provided additional metrics tied to osteoclastogenic signaling.
The authors emphasized that these assays allowed interrogation of how tumor-secreted factors alter bone cell mechanobiology—specifically how secretomes influence an osteocyte’s ability to transduce mechanical loading into anabolic cues. The preprint stated that differentiated MPC-2 cells formed functional networks suitable for these interrogations.
The report is a preprint and has not been peer reviewed. The abstract did not report specific quantitative proteomic results, individual secreted factors responsible for the observed effects, or full experimental parameters beyond the scaffold/perfusion approach, cell lines used, and the 0 versus 2 Gy irradiation condition. The authors did not provide dose–response radiation data or in vivo confirmation within the abstract. Remaining questions documented by the source include identification of the precise tumor-derived mediators that blunt osteocyte mechanosensing, whether findings generalize across additional ER+ and TN models, and how these in vitro secretome effects translate to bone remodeling in vivo.
Addressing those gaps will require targeted proteomic follow-up, neutralization or gain-of-function studies to nominate specific factors, and orthogonal in vivo models to test whether modulating the tumor secretome can restore flow-induced Sost suppression and improve bone outcomes in metastatic settings.